Dapagliflozin Viatris ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - zdravila, ki se uporabljajo pri diabetesu - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 in 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Lyfnua ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

lyfnua

merck sharp & dohme b.v. - gefapixant - cough - kašelj in hladni pripravki - lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.

Libmeldy ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

libmeldy

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - druga zdravila na živčnem sistemu - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Celsior raztopina za ohranjanje organov স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

celsior raztopina za ohranjanje organov

institut georges lopez - igl - glutaminska kislina; glutation; histidin; kalcijev klorid dihidrat; laktobionska kislina; magnezijev klorid heksahidrat; manitol; natrijev hidroksid; kalijev klorid - raztopina za ohranjanje organov - glutaminska kislina 2,94 g / 1 l  glutation0,92 g / 1 l  histidin4,65 g / 1 l  kalcijev klorid dihidrat0,04 g / 1 l  laktobionska kislina28,66 g / 1 l  magnezijev klorid heksahidrat2,64 g / 1 l  manitol10,93 g / 1 l  natrijev hidroksid4 g / 1 l  kalijev klorid1,12 g / 1 l; glutation 0,92 g / 1 l  histidin4,65 g / 1 l  kalcijev klorid dihidrat0,04 g / 1 l  laktobionska kislina28,66 g / 1 l  magnezijev klorid heksahidrat2,64 g / 1 l  manitol10,93 g / 1 l  natrijev hidroksid4 g / 1 l  kalijev klorid1,12 g / 1 l; histidin 4,65 g / 1 l  kalcijev klorid dihidrat0,04 g / 1 l  laktobionska kislina28,66 g / 1 l  magnezijev klorid heksahidrat2,64 g / 1 l  manitol10,93 g / 1 l  natrijev hidroksid4 g / 1 l  kalijev klorid1,12 g / 1 l; kalcijev klorid dihidrat 0,04 g / 1 l  laktobionska kislina28,66 g / 1 l  magnezijev klorid heksahidrat2,64 g / 1 l  manitol10,93 g / 1 l  natrijev hidroksid4 g / 1 l  kalijev klorid1,12 g / 1 l; laktobionska kislina 28,66 g / 1 l  magnezijev klorid heksahidrat2,64 g / 1 l  manitol10,93 g / 1 l  natrijev hidroksid4 g / 1 l  kalijev klorid1,12 g / 1 l; magnezijev klorid heksahidrat 2,64 g / 1 l  manitol10,93 g / 1 l  natrijev hidroksid4 g / 1 l  kalijev klorid1,12 g / 1 l; manitol 10,93 g / 1 l  natrijev hidroksid4 g / 1 l  kalijev klorid1,12 g / 1 l; natrijev hidroksid; kalijev klorid 1,12 g / 1 l - raztopine in pripravki za redčenje, vključno s tekočinami za izpiranje

Ontilyv ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

ontilyv

bial portela & companhia s.a. - opikapon - parkinsonova bolezen - anti-parkinsonska zdravila - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.